Full-Life Technologies announced on November 28 that it is acquiring Focus-X Therapeutics for $245 million.
Founded in 2020, Focus-X created a proprietary engineering platform to develop peptide radioligands that precisely deliver alpha or beta emitters to break down cancer cell DNA. The company is based in Watchung, New Jersey.
Shanghai-based Full-Life Technologies Limited is a fully integrated global radiotherapeutics company with operations in Europe and China. It was founded in 2021.
The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, and a peptide-focused discovery platform leveraging its radio technology manufacturing and logistics platforms to advance compounds into clinical development. The acquisition is expected to close in the first quarter of 2023.
Focus-X shareholders are eligible to receive from Full-Life an upfront payment, potential development, regulatory and sales-based milestones of up to $245 million and royalties on any commercial sales.
According to the LevinPro HC database, this acquisition marks the 133rd Biotechnology transaction of the year, a 24% increase from January 1, 2021 through November 28, 2021. The Biotechnology deal with the largest purchase price in 2022 was Pfizer Inc.’s acquisition of Biohaven Pharmaceutical Holding Company Limited for $11.6 billion in May.
